Lupus Foundation of America10m
New Study Highlights the Impact of Flares and Persistently Active Disease on Organ Damage in People with Systemic Lupus Erythematosus
known as lupus nephritis. Visit our Lupus Nephritis Information Center to learn about symptoms, diagnosis, and treatment options. Visit the Lupus Nephritis Information Center Close WEBINAR: What You ...
Turning pain into purpose: how a Cape Town runner aims to support a brave teen battling lupus
In standing together, we can ensure that Mercédi’s fight with lupus is not her fight alone. A community mobilised by empathy ...
Turning pain into purpose: How one Cape Town runner aims to support a brave teen battling lupus
In standing together, we can ensure that Mercédi’s fight with lupus is not her fight alone. A community mobilised by empathy ...
Healio7h
Impacts of CAR T-cell therapy in lupus often ‘not captured on SLEDAI’
Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that ...
PharmiWeb8h
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® ...
Pharmabiz15h
US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis
US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis: Basel Thursday, March 6, 2025, 09:00 Hrs [IST] Roche announced that the US Food and Drug Admini ...
PharmExec23h
FDA Accepts Roche’s Supplemental Biologics License Application for Gazyva/Gazyvaro in Lupus Nephritis
Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...